Management Profile: Aethlon Medical, Inc.

Executive Officers


James A. Joyce - Chairman, President and CEO
Edward C. Hall - Chief Financial Officer
Richard H. Tullis, Ph.D. - Vice President, Chief Science Officer



Senior Director, Communications


Jeffrey Richardson



Board of Directors


James A. Joyce

Franklyn S. Barry, Jr.

Edward G. Broenniman

Richard H. Tullis, Ph.D.


Scientific Advisory Board


Ken Alibek M.D., Ph.D., D.Sc.

Charles Bailey, Ph.D.

Jean-Claude Chermann, PhD

Larry Cowgill, D.V.M., Ph.D.

Pedro Cuatrecasas, M.D.

Nathan W. Levin, M.D.

Raveendran (Ravi) Pottathil, Ph.D.

Claudio Ronco, M.D.

Richard H. Tullis, Ph.D.

Regulatory & Clinical Affairs Advisor

Kenneth R. Michael, Pharm.D., R.A.C.


James A. Joyce
Chairman, President and CEO
As the founder of Aethlon Medical, Mr. Joyce has established the Company through a series of acquisitions and license agreements. In June of 2001, Mr. Joyce succeeded Franklyn S. Barry, Jr. as President and CEO of Aethlon Medical. Since that time, he has led the Company’s transition from treating harmful metals to treating HIV/AIDS, Hepatitis-C, and most recently, infectious biowarfare pathogens.

From February 1993 until founding Aethlon in May of 1998, Mr. Joyce was Chief Executive Officer of James Joyce & Associates, an organization that provided senior management consulting and investment banking advisory services to both private and publicly traded companies. Previously, Mr. Joyce was Chief Executive Officer of Mission Labs, Inc., and a principal in charge of U.S. operations for London Zurich Securities, Inc. Mr. Joyce is a graduate of the University of Maryland.


Edward C. Hall
Chief Financial Officer

Mr. Hall has over 25 years corporate executive financial management experience and recently was vice president finance and chief financial officer of Chromagen, Inc., a private biotech tools start-up with proprietary fluorescent detection technology. Prior to this, he was CFO of Cytel Corporation, a public biotech company and CFO of Medical Device Technologies, Inc., a public medical device company. Mr. Hall received his BS in engineering from Princeton University and MBA from the Harvard Business School. Mr. Hall currently is also a partner with Tatum CFO Partners, LLP.


Richard H. Tullis, Ph.D.
Vice President, Chief Science Officer
Dr. Tullis has extensive biotechnology management and research experience, and is the founder of Syngen Research, a wholly-owned subsidiary of Aethlon Medical, Inc. Dr. Tullis became a Vice President and Director of Aethlon Medical, Inc. in January of 2000, and succeeded Dr. Clara M. Ambrus as Chief Scientific Officer in June of 2001. Previously, Dr. Tullis co-founded Molecular Biosystems, Inc., a former NYSE company. At Molecular Biosystems, Dr. Tullis was Director of Research and Development, Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxy-phosphorochloridites. Dr. Tullis also co-developed the first applications of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985, Dr. Tullis founded, and served as President and CEO of Synthetic Genetics, Inc., a pioneer in custom DNA synthesis, which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interim-CEO of Genetic Vectors, Inc., which completed its IPO under his management, and was co-founder of DNA Sciences, Inc., a company that was eventually acquired by Genetic Vectors. Dr Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive post-doctoral work at UCSD, USC, and The Scripps Research Institute.


Jeffrey Richardson
Senior Director, Communications
Mr. Richardson brings nearly 20 years of senior leadership in global public relations for research-based medical companies. Prior to joining Aethlon, Mr. Richardson was Director, Global Public Relations for Amgen, the world's largest biotechnology company. Previously, he held senior communications positions with both Glaxo and DuPont. Mr. Richardson will be responsible for establishing government and military communication initiatives and will manage medical industry and investor relations programs.



Board of Directors

James A Joyce
As the founder of Aethlon Medical, Mr. Joyce has established the Company through a series of acquisitions and license agreements. In June of 2001, Mr. Joyce succeeded Franklyn S. Barry, Jr. as President and CEO of Aethlon Medical. Since that time, he has led the Company’s transition from treating harmful metals to treating HIV/AIDS, Hepatitis-C, and most recently, infectious biowarfare pathogens.

From February 1993 until founding Aethlon in May of 1998, Mr. Joyce was Chief Executive Officer of James Joyce & Associates, an organization that provided senior management consulting and investment banking advisory services to both private and publicly traded companies. Previously, Mr. Joyce was Chief Executive Officer of Mission Labs, Inc., and a principal in charge of U.S. operations for London Zurich Securities, Inc. Mr. Joyce is a graduate of the University of Maryland.

Franklyn S. Barry, Jr.
Franklyn S. Barry, Jr., is the former President and CEO of Aethlon Medical, Inc. and Hemex, Inc. He has over 25 years of experience in managing and building companies. Mr. Barry became director of Aethlon Medical, Inc. in March of 1999, and is the past President of Fisher-Price, a children's products company, and was co-founder and CEO of Software Distribution Services, which today operates as Ingram Micro-D, a global leader in the distribution of personal computer products. He received a BA from Harvard University, and an MBA from the Harvard Graduate School of Business Administration.


Edward G. Broenniman
Edward G. Broenniman is an entrepreneur with substantial experience in the formation and development of high technology businesses. He became a director of Aethlon Medical, Inc. in March of 1999. Mr. Broenniman has 30 years of management and executive experience with high-tech, privately held growth firms where has he served as CEO, COO, or corporate advisor. He recently served on the Board of Directors of publicly traded QuesTech (acquired by CACI International), and currently is a director of four privately-held companies. His non-profit Boards are the Dingman Center for Entrepreneurship’s Board of Advisors at the University of Maryland, the National Association of Corporate Directors, the National Capital Chapter, and the Board of the Association for Corporate Growth. Mr. Broenniman holds a BA from Yale University and an MBA from Stanford University.


Richard H Tullis, Ph.D.
Dr. Tullis has extensive biotechnology management and research experience, and is the founder of Syngen Research, a wholly-owned subsidiary of Aethlon Medical, Inc. Dr. Tullis became a Vice President and Director of Aethlon Medical, Inc. in January of 2000, and succeeded Dr. Clara M. Ambrus as Chief Scientific Officer in June of 2001. Previously, Dr. Tullis co-founded Molecular Biosystems, Inc., a former NYSE company. At Molecular Biosystems, Dr. Tullis was Director of Research and Development, Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxy-phosphorochloridites. Dr. Tullis also co-developed the first applications of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985, Dr. Tullis founded, and served as President and CEO of Synthetic Genetics, Inc., a pioneer in custom DNA synthesis, which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interim-CEO of Genetic Vectors, Inc., which completed its IPO under his management, and was co-founder of DNA Sciences, Inc., a company that was eventually acquired by Genetic Vectors. Dr Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive post-doctoral work at UCSD, USC, and The Scripps Research Institute.

Scientific Advisory Board

Ken Alibek M.D., Ph.D., D.Sc.
Dr. Alibek is the Executive Director of Education at the National Center for Biodefense at George Mason University (GMU), and is a Distinguished Professor at GMU as well. Dr. Alibek specializes in medical and scientific research dedicated to developing new forms of protection against biological weapons and other infectious diseases. Formerly, Dr. Alibek was a Soviet Army Colonel, and served as First Deputy Chief of the civilian branch of the Soviet Union’s biological weapons program until he defected to the United States in 1992 and subsequently served as a consultant to numerous U.S. government agencies in the areas of medical microbiology, biological weapons defense, and biological weapons nonproliferation. Dr. Alibek has worked with the National Institutes of Health, testified extensively before the U.S. Congress on nonproliferation of biological weapons and is the author of Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World--Told from Inside by the Man Who Ran It, published by Random House Books. He holds numerous patents, is widely published in science journals, and has provided over 300 lectures and presentations to military and civilian universities, as well as foreign governments. The December 2003 issue of the Acumen Journal of Life Sciences named Dr. Alibek as one of top five biological warfare experts in the nation.

Charles Bailey, Ph.D.
Dr. Bailey is the former commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Dr. Bailey has 25 years' U.S. Army experience in R&D and management in infectious diseases and biological warfare defense. As an officer of the Defense Intelligence Agency, Dr. Bailey wrote extensively on foreign biological warfare capabilities. Dr. Bailey is currently the Executive Director for Research & International Relations at the National Center for Biodefense at George Mason University (GMU), and is a Distinguished Professor of Biology at GMU as well. The Acumen Journal of Life Sciences named Dr. Bailey as one of the top five biological warfare experts in the nation.

Jean-Claude Chermann, PhD
Dr. Chermann is a pioneer in the study of retroviruses, and was the principal investigator of the research team that collaborated in the first isolation and characterization of HIV (The AIDS Virus) at the Pasteur Institute in 1983.

Included among Dr. Chermann’s research publications on HIV/AIDS are:

• First isolation of HIV, description of the cytopathic effect for CD4 +cells, the CD4 +cells as target and the isolation of the virus in haemophiliacs and in the African people.
• The confirmation that HIV is a retrovirus by the description of the reverse transcriptase. The demonstration that the HIV retrovirus is a lentivirus.
• The demonstration of the transmission by blood by isolating the virus in the donor and in the recipient. The description of the methods of inactivation of HIV.
• The first inoculation of chimpanzees and the demonstration of this infection.
• The association of persistent general lymphadenopathy and the infection with HIV.
• The first use of an anti-retroviral agent in humans for the treatment of AIDS patients.
• The first demonstration of the infection by the detection of antibodies in US patients.
• The demonstration of the transmission by needle sharing and heterosexual transmission.
• The first description of the genomic variability of HIV.

Larry Cowgill, D.V.M., Ph.D.
Dr. Cowgill is a Professor in the Department of Medicine and Epidemiology at the School of Veterinary Medicine, University of California--Davis and has nearly 30 years of experience as a clinical instructor in small animal internal medicine, nephrology, and hemodialysis. He currently Heads the Companion Animal Hemodialysis Units at the Veterinary Medical Teaching Hospital at UC Davis and the UC Veterinary Medical Center-San Diego.

Dr. Cowgill is also Associate Dean for Southern California Clinical Programs and is Co-Director of the University of California Veterinary Medical Center-San Diego. Prior to his appointment at the University of California, he was a National Institutes of Health (NIH) Special Research Fellow at the University of Pennsylvania School of Veterinary Medicine and at the Renal Electrolyte Section at the University of Pennsylvania School of Medicine, where he conducted research in basic renal physiology and clinical nephrology.

Dr. Cowgill received his D.V.M. from the University of California--Davis School of Veterinary Medicine and his Ph.D. in Comparative Medical Sciences from the University of Pennsylvania, where he also completed his internship and Residency training in Small Animal Internal Medicine. He became a Diplomat of the American College of Veterinary Internal Medicine in 1977. Dr. Cowgill has published extensively in the area of veterinary nephrology and has established a Clinical Fellowship in Renal Medicine and Hemodialysis, which is the first of its kind in veterinary Medicine.

Pedro Cuatrecasas, M.D.
Dr. Cuatrecasas was President of the Pharmaceutical Research Division of Parke-Davis Co., and Corporate Vice President for Warner Lambert Company from 1989 until his retirement in 1997. From 1986 to 1989, he served as Sr. Vice President and Director of Glaxo Inc. For the prior ten years, he was Vice President of Research and Development and Director, of the Burroughs Wellcome Company.

During his career in pharmaceutical research, he was involved in the discovery, development and marketing registration of more than forty novel medicines, including: zidovudine (AZT, AIDS), acyclovir (Zovirax, anti-herpes), permethrin (Rid, head and body lice), bupropion (Wellbutrin, antidepressant), calsfosceril (Exosurf, infant acute respiratory distress), remifentanil (Ultiva, analgesic/anesthetic), sumatriptan (Imigran, migraine), salmeterol (Serement, asthma), tacrine (Cognex, Alzheimers), gabapentin (Neurontin, epilepsy and neuropathic pain), troglitazone (Rezulin, diabetes), and atorvastatin (Lipitor, cholesterol lowering).

Dr. Cuatrecasas is widely recognized for the invention and development of affinity chromatography, a process utilized within the Aethlon HemopurifierTM. He is a member of the National Academy of Sciences, The Institute of Medicine, and the American Academy of Arts & Sciences. He is a past recipient of the Wolf Prize in Medicine, the Washington University School Of Medicine Alumni Achievement Award, the Johns Hopkins University Distinguished Alumnus Award, the City of Medicine Award, and the North Carolina Governor’s Medal Award in Science. Dr. Cuatrecasas has authored over 400 original publications.

Nathan W. Levin, M.D.
Dr. Levin is recognized as a leading authority within the Hemodialysis industry. He is the Medical and Research Director of the Renal Research Institute, LLC, a joint venture between Fresenius Medical Care - North America and Beth Israel Medical Center, New York. Dr. Levin also serves as Professor of Clinical Medicine at the Albert Einstein College of Medicine.

Raveendran (Ravi) Pottathil, Ph.D.
Dr. Ravi Pottathil is a recognized authority in the field HIV/AIDS diagnostics and therapeutics. In this regard, Dr. Pottathil was the Section Manager for Retroviruses (focus on HIV and HCV) and Tumor markers and PCR diagnostics at Hoffman La Roche from 1985 to 1992. Upon completing his tenure at Roche, Dr. Pottathil co-founded Specialty Biosystems, Inc, a venture of Specialty Labs, one of the largest independent reference laboratories in California. Dr. Pottathil has also advised the World Health Organization’s Sexually Transmitted Diseases and Global Vaccination Program.

Dr. Pottathil has worked with Dr. Robert Huebner of the NIH in immunology and virology at The Jackson Laboratory, and with Drs. David Lang and Wolfgang Joklik at Duke University on interferons, anti-tumor RNAs and antigenic suppression of tumorigenic retroviruses. Academic positions include: Assistant Professor at the University of Maryland School of Medicine; Associate Professor at the City of Hope Medical Center in Duarte, California where he published extensively with Dr. Pedro Cuatrecasas (one of developers of affinity chromatography); and Adjunct Professor in Cellular and Molecular Biology at Down State Medical Center and Rutgers University.

As a virologist and molecular biologist, Dr. Pottathil has over 40 refereed publications to his credit and has been a Director of OncQuest, Inc., GeneQuest, Inc., Specialty Laboratories Asia in Singapore and Specialty Ranbaxy in India. Currently, Dr. Pottathil is the President of AccuDx, Inc. a pharmaceutical diagnostics company he founded in 1996.

Claudio Ronco, M.D.
Dr. Ronco is the Director of the Dialysis and Renal Transplantation Programs of St. Bartolo Hospital in Vicenza, Italy. He has published seventeen books on Nephrology and Dialysis, and has written or co-authored over 350 scientific articles. Dr. Ronco also serves on the editorial board of twelve scientific journals, is a director of three international scientific societies, and is recognized as being instrumental in the introduction of continuous hemofiltration and high flux dialysis in Europe.

Richard H. Tullis - Ph.D.
Dr. Tullis has extensive biotechnology management and research experience, and is the founder of Syngen Research, a wholly-owned subsidiary of Aethlon Medical, Inc. Dr. Tullis became a Vice President and Director of Aethlon Medical, Inc. in January of 2000, and succeeded Dr. Clara M. Ambrus as Chief Scientific Officer in June of 2001. Previously, Dr. Tullis co-founded Molecular Biosystems, Inc., a former NYSE company. At Molecular Biosystems, Dr. Tullis was Director of Research and Development, Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxy-phosphorochloridites. Dr. Tullis also co-developed the first applications of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985, Dr. Tullis founded, and served as President and CEO of Synthetic Genetics, Inc., a pioneer in custom DNA synthesis, which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interim-CEO of Genetic Vectors, Inc., which completed its IPO under his management, and was co-founder of DNA Sciences, Inc., a company that was eventually acquired by Genetic Vectors. Dr Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive post-doctoral work at UCSD, USC, and The Scripps Research Institute.


Regulatory & Clinical Affairs Advisor

Kenneth R. Michael, Pharm.D., R.A.C.
Kenneth R. Michael, Pharm. D., R.A.C., is the former Vice President of Regulatory Affairs and Quality Assurance at Siemens Medical Systems, and is the Founder, past President and Chairman of The Regulatory Affairs Professionals Society (RAPS), an international professional society representing over 8000 healthcare Regulatory Affairs professionals. He is also the Founder of the local San Diego Regulatory Affairs Network (SDRAN). Currently, Dr. Michael serves as the President of KRM Associates LLC, a regulatory and clinical affairs consulting organization, and frequently teaches regulatory, quality and management professionals at various university and medical institutions. He is an active director of several medical device, and pharmaceutical organizations.